| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 04/15/2004 | US20040072168 Novel deoxynucleoside kinase enzyme variants |
| 04/15/2004 | US20040071738 Hypo-allergenic pollen protein treated with thioredoxin, nicotinamide adenine dinucleotide phosphate- thioredoxin reductase (NTR) and reduced nicotinamide adenine dinucleotide phosphate (NADPH) |
| 04/15/2004 | US20040071737 Polysaccharides and/or glycopeptides preparable from keratinophilic fungi and yeasts; vaccines, immunomodulators, and antiallergens; precipitation and separation of supernatant; treatment with mineral or organic acid |
| 04/15/2004 | US20040071717 Recombinant DNA encoding the major allergen of plantago lanceolata pollen, Pla I 1, and applications thereof |
| 04/15/2004 | US20040071714 A gene expressed polypeptide is used in food, for treating food allergy |
| 04/15/2004 | US20040071712 Modified peptides as therapeutic agents |
| 04/15/2004 | US20040071709 Corona-virus-like particles comprising functionally deleted genomes |
| 04/15/2004 | US20040071699 An antagonists, or agonists, producing antibodies, used as immunotherapy treating allergy, acquired immune deficiency syndrome, autoimmune diabetes, thyroiditis |
| 04/15/2004 | US20040071693 Humanised antibodies |
| 04/15/2004 | US20040071691 Including compatible solute; enhancing effectiveness of protein containing active material; reducing cytotoxic activity |
| 04/15/2004 | US20040071673 Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease |
| 04/15/2004 | US20040071655 Binding agent |
| 04/15/2004 | US20040069523 Use of Vitamin D-Derivatives in the Treatment of Osteoporosis and related bone disorders, as well as novel vitamin D3-Deviratives |
| 04/15/2004 | DE4325927B4 Taxol enthaltender Medikamentierungskit Taxol-containing Medikamentierungskit |
| 04/15/2004 | CA2503674A1 Quinazolin-4-one derivatives |
| 04/15/2004 | CA2500935A1 Novel compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection |
| 04/15/2004 | CA2500844A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 04/15/2004 | CA2500433A1 Recombinant intracellular pathogen immunogenic compositions and methods for use |
| 04/15/2004 | CA2500413A1 Method of strengthening foreign epitope presentation by mhc class i by inhibiting tap activity |
| 04/14/2004 | EP1408113A1 Human type antihuman ige receptor antibody and antibody fragment |
| 04/14/2004 | EP1408033A1 Dibenzocycloheptene compound |
| 04/14/2004 | EP1407795A2 Nasal delivery devices |
| 04/14/2004 | EP1407044A2 Rna interference mediating small rna molecules |
| 04/14/2004 | EP1407004A2 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| 04/14/2004 | EP1406930A2 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 04/14/2004 | EP1406928A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 04/14/2004 | EP1406915A2 Antisense modulation of transforming growth factor beta receptor ii expression |
| 04/14/2004 | EP1406899A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 04/14/2004 | EP1406898A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 04/14/2004 | EP1406894A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 04/14/2004 | EP1406878A1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies |
| 04/14/2004 | EP1406876A1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| 04/14/2004 | EP1406875A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 04/14/2004 | EP1406873A2 Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| 04/14/2004 | EP1406872A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 04/14/2004 | EP1406867A2 Thiolalkyl benzoic acid derivatives |
| 04/14/2004 | EP1406866A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 04/14/2004 | EP1406865A2 Succinic acid derivatives |
| 04/14/2004 | EP1406700A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 04/14/2004 | EP1406667A2 METHODS FOR INCREASING i IN VIVO /i EFFICACY OF OLIGONUCLEOTIDES AND INHIBITING INFLAMMATION IN MAMMALS |
| 04/14/2004 | EP1406664A2 Targeting chemical compounds to cells |
| 04/14/2004 | EP1406660A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 04/14/2004 | EP1406656A2 METHODS OF ADMINISTERING ANTI-TNF$g(a) ANTIBODIES |
| 04/14/2004 | EP1406653A2 T cell regulatory genes and methods of use thereof |
| 04/14/2004 | EP1406650A1 Use of poly-glu, tyr and t cells treated therewith for neuroprotection therapy |
| 04/14/2004 | EP1406644A2 Modified proteins, designer toxins, and methods of making thereof |
| 04/14/2004 | EP1406641A2 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
| 04/14/2004 | EP1406632A2 Substituted 3-aryl-5-aryl- 1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 04/14/2004 | EP1406622A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 04/14/2004 | EP1406618A2 Use of nk-1 receptor antagonists with pyridinic structure for the treatment of brain, spinal or nerve injury |
| 04/14/2004 | EP1406609A2 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 04/14/2004 | EP1406602A2 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors |
| 04/14/2004 | EP1406599A1 Cosmetic and dermatological preparations containing creatine for treating and actively preventing dry skin and other negative alterations of the physiological homeostasis of healthy skin |
| 04/14/2004 | EP1301522A4 Novel compounds and methods |
| 04/14/2004 | EP1200419B1 Aminothiazole derivatives and their use as crf receptor ligands |
| 04/14/2004 | EP1181038B1 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals |
| 04/14/2004 | EP1115708B1 Aminoalkyl-3,4-dihydroquinoline derivates as no-synthase inhibitors |
| 04/14/2004 | EP1073641B1 New substituted amides, their production and their use |
| 04/14/2004 | EP1054867B1 Antivirals |
| 04/14/2004 | EP1042315B1 Cyclic imide-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic and immunosuppressive agents |
| 04/14/2004 | EP0948495B1 Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
| 04/14/2004 | EP0935465B1 Novel substituted imidazole compounds |
| 04/14/2004 | EP0925298B1 Substituted 6,6-hetero-bicyclic derivatives |
| 04/14/2004 | EP0883406B1 Use of il-7 for treating auto-immune diseases and insulin-dependent diabetes mellitus in particular |
| 04/14/2004 | EP0765392B1 Interleukin-5 specific recombinant antibodies |
| 04/14/2004 | CN1489628A Compounds and methods for treatment and diagnosis of chlamydial infection |
| 04/14/2004 | CN1489590A Compounds specific to adenosine A1, A2, and A3 receptor and uses thereof |
| 04/14/2004 | CN1489588A Thiazolyl-oxazolyl-pyrrolyl-and imidazolyl-acid amide derivatives useful as inbibitors of PDE 4 isozymes |
| 04/14/2004 | CN1489586A Indazolyl-substituted pyrroline compounds as kinase inhibitor |
| 04/14/2004 | CN1489581A 喹唑啉酮衍生物 Quinazolinone derivatives |
| 04/14/2004 | CN1489576A Cannabinod receptor ligands |
| 04/14/2004 | CN1489480A Procedure and composition of treatment and/or care of eye |
| 04/14/2004 | CN1489476A Method of preparing biological materials and preparation produced using same |
| 04/14/2004 | CN1489473A Silensed anti-CD 28 antibodies and use thereof |
| 04/14/2004 | CN1489472A Improved mycoplasma hyopneumoniae bacterin vaccine |
| 04/14/2004 | CN1489467A Pharmacentical formulation comprising pyrazolo[4,3-d] pyrimdine and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists |
| 04/14/2004 | CN1488365A Composition with intelligence-development, immunological regulation and fatigure resistance |
| 04/14/2004 | CN1488346A Melatonin two-layer release-controlled tablet and preparing process thereof |
| 04/14/2004 | CN1145693C Amino-terminally truncated MCP-2 as chemokine antagnosits |
| 04/14/2004 | CN1145637C Thio-substituted peptides as inhibitors for metalloproteinases and tnfliberation |
| 04/14/2004 | CN1145613C Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing same |
| 04/14/2004 | CN1145606C 2-aminotetrahydronaphthalene, process for their preparation, and pharmaceutical composition for prevention and therapeutic treatment of in flammatory and lor autoimmune pathologies |
| 04/14/2004 | CN1145493C Materials for preventing arteriosclerosis |
| 04/14/2004 | CN1145485C 8-chloro-6,11-dihydro-11-(4-piperidy lidene)-5H-benzo[5,6] cyclohepta [1,2,-b] pyridine oral compositions |
| 04/13/2004 | US6720452 Adamantane derivatives |
| 04/13/2004 | US6720427 Used to treat abnormal cell growth and central nervous system disorders |
| 04/13/2004 | US6720346 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation |
| 04/13/2004 | US6720336 4,4-biarylpiperidine derivatives |
| 04/13/2004 | US6720328 Treating allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) |
| 04/13/2004 | US6720325 CCR5 antagonists useful for treating aids |
| 04/13/2004 | US6720321 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
| 04/13/2004 | US6720319 Compounds useful as reversible inhibitors of cysteine proteases |
| 04/13/2004 | US6720304 Conjugate comprising a folic acid antagonist and a carrier |
| 04/13/2004 | US6720146 Nucleotide sequences coding polypeptide for use in the treatment, diagnosis and prevention of ovarian cancer |
| 04/13/2004 | US6720002 Solubility and storage stability while maintaining bioavailability of drug |
| 04/13/2004 | US6719976 Administering monomolecular multi-epitope peptide prepared by binding t-cell epitope regions derived from different allergens |
| 04/13/2004 | US6719972 Induce antigen specific apoptosis in activated t cells; ligands with monoclonal anti-ctla4 antibody that binds to an epitope of ctla4 |
| 04/08/2004 | WO2004029192A2 Producing method of tien hsien liquid |
| 04/08/2004 | WO2004029080A1 Compound binding to leukocytes and medicinal composition containing the compound in labeled state as the active ingredient |
| 04/08/2004 | WO2004029054A1 Novel adenine compound and use thereof |